Clinical Trial: Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07693452) titled 'Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms' on July 03.

Brief Summary: This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Study Start Date: June 18

Study Type: INTERVENTIONAL

Condition: Appendiceal Mucinous Neoplasm Pseudomyxoma Peritonei

Intervention: DRUG: Metformin

Given PO

Recruitment Status: RECRUITING

Sponsor: University of California, Irvine

Information provided by (Responsible Party): Oliver Eng, University of California, Irvine

Disclaimer:...